Table 1 |
||
|
Characteristics of the patients with polymyositis/dermatomyositis for serum analysis |
||
|
Healthy control serum (n = 20) |
PM/DM patient serum (n = 29) |
|
|
|
||
|
Number of PM/DM |
7/22 |
|
|
Number of males/females |
9/11 |
9/20 |
|
Age (years) |
38.6 ± 2.1 |
55.3 ± 2.5 |
|
Duration of the disease (months) |
21.6 ± 8.2 |
|
|
Number of cases of new onset/flare |
23/6 |
|
|
Number of antinuclear antibody-positive |
9 (n = 22) |
|
|
Number of anti-Jo-1 antibody-positive |
8 (n = 22) |
|
|
Serum creatinine kinase (IU/l)a |
4,063.8 ± 1,466.9 |
|
|
Manual muscle testing score |
39.0 ± 1.4 (n = 18) |
|
|
Number of patients with ILD |
19 |
|
|
AaDO2 with ILD |
31.5 ± 7.9 (n = 19) |
|
|
Treatment at time of blood sampling |
||
|
Untreated |
19 |
|
|
Prednisolone alone |
4 |
|
|
Prednisolone and cyclosporine |
5 |
|
|
Prednisolone and methotrexate |
1 |
|
|
|
||
|
Data presented as n or mean ± standard error of the mean. Antinuclear antibody was analyzed by immunofluorescence assay. The titer of anti-Jo-1 antibody was investigated by enzyme immunoassay. Although in some patients anti-dsDNA (n = 17), anti-RNP (n = 13), anti-Scl-70 (n = 4), and anti-SS-A (n = 12) antibodies and rheumatoid factor (n = 16) were analyzed, they were all negative. AaDO2, alveolar-arterial oxygen pressure difference; ILD, interstitial lung disease; PM/DM, polymyositis/dermatomyositis. aNormal range: male < 197 IU/l, female < 180 IU/l. |
||
|
Suzuki et al. Arthritis Research & Therapy 2012 14:R48 doi:10.1186/ar3761 |
||
